http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-057823-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a910d33c239980f3a705e312c5bad6a |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| filingDate | 2006-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_04fbeb5209c87649b889e1020c794317 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ca522bcb5779e48c5bf8ccf0e0ab01ad http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_26f80de801c1e6e2ce59c816fa56e07b |
| publicationDate | 2007-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-057823-A1 |
| titleOfInvention | CHEMICAL COMPOUNDS DERIVED FROM QUINAZOLINE, A METHOD FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITION |
| abstract | There is an anti-proliferative effect, which occurs totally or partially through the inhibition of tyrosine kinase of erbB2 receptors, in a warm-blooded animal, such as man. These compounds are useful in the prevention or treatment of solid tumor diseases in warm animals. Process of preparation of the compounds and pharmaceutical composition based on those. Claim 1: A quinazoline derivative characterized in that it responds to formula (1), wherein: R1 is selected from hydrogen, hydroxy, C1-4 alkoxy and C1-4 alkoxy-C1-4 alkoxy; G1, G2, G3 and G4 are each independently selected from hydrogen and halogen; X1 is selected from SO2, CO, SO2N (R6) and C (R6) 2, where each R6 is independently selected from hydrogen and C1-4 alkyl; Q1 is aryl or heteroaryl, wherein said aryl or heteroaryl group optionally contains one or more substituents independently selected from halogen, cyano, C1-4 alkoxy and C1-4 alkyl; R2 and R3, which may be the same or different, are selected from hydrogen, C2-4 alkenyl, C2-4 alkynyl and C1-4 alkyl, which C1-4 alkyl optionally contains one or more hydroxy substituents, or R2 and R3 together with the carbon atom to which they are attached they form a cyclopropyl ring; R4 and R5, which may be the same or different, are selected from hydrogen, C3-4 alkenyl, C3-4 alkynyl and C1-4 alkyl, which C1-4 alkyl optionally contains one or more substituents independently selected from halogen, cyano, hydroxy, amino, C1-4 alkylamino, di- (C1-4 alkyl) amino and C1-4 alkoxy; or R4 and R5 together with the nitrogen atom to which they are attached form a 4, 5, 6 or 7-membered heterocyclic ring that optionally contains one or more heteroatoms independently selected from oxygen, S, SO, SO2 and N (R7), where R7 is selected from hydrogen and C1-4 alkyl, and where any heterocyclic ring formed by R4, R5 and the nitrogen atom to which they are attached optionally contains one or more substituents independently selected from halogen, cyano, hydroxy, C1-4 alkyl and C1-4 alkoxy; and where any heterocyclic ring formed by R4, R5 and the nitrogen atom to which they are attached optionally contains 1 or 2 oxo or thioxo substituents; or a salt acceptable for pharmaceutical use thereof. |
| priorityDate | 2005-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 35.